» Articles » PMID: 35211767

Discovery of a Potent Cytotoxic Agent That Promotes G/M Phase Cell Cycle Arrest and Apoptosis in a Malignant Human Pharyngeal Squamous Carcinoma Cell Line

Overview
Journal Int J Oncol
Specialty Oncology
Date 2022 Feb 25
PMID 35211767
Authors
Affiliations
Soon will be listed here.
Abstract

Squamous cell carcinoma is the major form of malignancy that arises in head and neck cancer. The modest improvement in the 5‑year survival rate underpins its complex etiology and provides the impetus for the discovery of new therapeutics. The present study describes the discovery of an indole‑based small molecule (24a) that was a potent cytotoxic agent with antiproliferative and pro‑apoptotic properties against a pharyngeal carcinoma cell line, Detroit 562, effectively killing the cells at a half‑maximal inhibitory concentration of 0.03 µM, as demonstrated using cell proliferation studies. The antiproliferative property of 24a was demonstrated by its ability to promote G/M blockade, as assessed by cell cycle analysis using flow cytometry and the monitoring of real‑time cell cycle progression by the fluorescence ubiquitination‑based cell cycle indicator. This pro‑apoptotic property is supported by the promotion of TUNEL‑staining and increase in the activities of caspases‑3/7 and ‑6, in addition to the expression of death receptors and the cleavage of poly (ADP‑ribose) polymerase 1 protein as demonstrated by western blotting. Given that Detroit 562 lacks functional p53, it is suggested that 24a acts independently of the tumor suppressor.

Citing Articles

N-Aryl Benzimidazole and Benzotriazole Derivatives and Their Hybrids as Cytotoxic Agents: Design, Synthesis and Structure-Activity Relationship Studies.

Aleksandrova Y, Nikolaeva N, Shagina I, Smirnova K, Zubishina A, Khlopotinin A Molecules. 2024; 29(22).

PMID: 39598749 PMC: 11596563. DOI: 10.3390/molecules29225360.


Design, Synthesis and Cytotoxic Activity Evaluation of Newly Synthesized Amides-Based TMP Moiety as Potential Anticancer Agents over HepG2 Cells.

Al-Warhi T, Aldhahrani A, Althobaiti F, Fayad E, Abu Ali O, Albogami S Molecules. 2022; 27(12).

PMID: 35745081 PMC: 9227250. DOI: 10.3390/molecules27123960.

References
1.
Georgakilas A, Martin O, Bonner W . p21: A Two-Faced Genome Guardian. Trends Mol Med. 2017; 23(4):310-319. DOI: 10.1016/j.molmed.2017.02.001. View

2.
Deyoung M, Ellisen L . p63 and p73 in human cancer: defining the network. Oncogene. 2007; 26(36):5169-83. DOI: 10.1038/sj.onc.1210337. View

3.
Grem J . 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000; 18(4):299-313. DOI: 10.1023/a:1006416410198. View

4.
Liu D, Song H, Xu Y . A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene. 2009; 29(7):949-56. PMC: 2837937. DOI: 10.1038/onc.2009.376. View

5.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View